palbociclib with endocrine therapy impact on time to chemotherapy
Published 2 years ago • 68 plays • Length 4:42Download video MP4
Download video MP3
Similar videos
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
6:46
determining endocrine therapy for premenopausal breast cancer patients: practical considerations
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
1:10
palbociclib, pembrolizumab, and endocrine therapy in hr /her2- breast cancer
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
7:09
palbociclib endocrine therapy vs capecitabine for hr-positive her2-negative breast cancer: pearl
-
13:22
palbociclib and breast cancer
-
2:21
palbociclib with adjuvant endocrine therapy in early breast cancer - pallas study
-
3:38
efficacy and quality of life outcomes with ribociclib plus letrozole vs letrozole alone for mbc
-
24:33
session 9: adjuvant endocrine therapy for premenopausal women: risk stratification, type & duration
-
0:27
how to cope with tamoxifen and letrozole
-
2:43
adjuvant palbociclib strikes out in pallas trial | erica mayer
-
9:34
metastatic breast cancer: hormone receptor positive
-
1:26
dr. burstein on adjuvant endocrine therapy for er breast cancer
-
0:09
breast cancer's dirty little secret
-
27:44
new targeted agents in breast cancer palbociclib & beyond
-
48:22
adjuvant endocrine therapy for high-risk breast cancer
-
8:18
endocrine therapy in premenopausal women with hr breast cancer
-
1:25
dr. ellis on neoadjuvant endocrine therapy for breast cancer